Development PipelineDisitamab vedotin
a novel, investigational antibody–drug conjugate directed to HER2
The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
RC48 G001: HER2-expressing locally advanced or metastatic urothelial cancer (DV ± pembrolizumab)
High-level synopsis of disitamab vedotin and ongoing clinical trials
Detailed information about disitamab vedotin clinical trials